Significant fall in Hepatitis C deaths
And new treatments mean fewer people now require liver transplants Related items fromOnMedica Range of new and costly drugs added to WHO ‘essentials’ list UK joins fight against Ebola GPs should administer Hep C therapy, says WHO UK falls behind other nations in preventing avoidable death Common anti-parasitic could be new tool for malaria control
Soft Matter, 2019, Accepted Manuscript DOI: 10.1039/C9SM00677J, PaperAnil Kumar Dasanna, Dmitry A. Fedosov, Gerhard Gompper, Ulrich Sebastian Schwarz Red blood cells in shear flow show a variety of different shapes due to the complex interplay between hydrodynamics and membrane elasticity. Malaria-infected red blood cells become generally adhesive and... The content of this RSS Feed (c) The Royal Society of Chemistry
We examined the efficacy of 2 supplementary KT education approaches delivered directly to patients.Study DesignProspective, 3-arm parallel-group, randomized, controlled trial.Settings &ParticipantsAdult, black, and white low-income patients receiving dialysis in Missouri.InterventionPatients were randomly assigned to 1 of 3 educational conditions: (1) standard of care, usual KT education provided in dialysis centers (control); (2) Explore Transplant @ Home patient-guided, 4 modules of KT education sent directly to patients using print, video, and text messages; and (3) Explore Transplant @ Home educator-guided, the pat...
A 71-year-old with Stanford type B aortic dissection treated with Cook Medical (Bloomington, IN) ProForm ™ stent grafts 3 years previously was referred to the nephrology outpatient clinic for asymptomatic new-onset renal impairment. Other comorbidities were chronic hepatitis B, diabetes mellitus, and hypertension. Clinic blood pressure was 152/80 mm Hg, but physical examination was otherwise unremar kable. Serum creatinine was 142 μmol/l, urine protein-to-creatinine ratio 4.07 g/g, and glomerular hematuria was present (210 red cells) without pyuria on urine microscopy.
ATHENA, published in this edition of Kidney International, is the third contemporary, multicenter, randomized, controlled trial to compare de novo use of everolimus, calcineurin inhibitor, and steroids to our current standard of care, mycophenolate, tacrolimus, and steroids, in kidney transplant recipients. This commentary highlights the strengths and significant weaknesses of ATHENA. It then seeks to distill the key messages from the 3 trials, ATHENA, TRANSFORM, and US92, and considers the role of everolimus in kidney transplantation today.
We read with great interest the B-cell analysis by Erpicum et al.1 in kidney transplant (KTx) patients, who were infused with third-party mesenchymal stromal cells (MSCs) 2 to 3 days post-KTx. Based on their experience in 10 KTx patients, the investigators reported that there was a decrease in B cells (CD19+) in the MSC-treated group from day 30 (D-30) until D-365. Furthermore, no change in transitional B cells (CD19+CD24+CD38hi) was observed in the MSC-treated group in comparison to the concurrent control subjects.
Conclusion: SOF/VEL followed by SOF/VEL/VOX leads to comparable cure rates in the overall CHC population relative to the GLE/PIB treatment pathway. Based on wholesale acquisition prices, the SOF/VEL treatment pathway led to lower lifetime costs. PMID: 31204882 [PubMed - as supplied by publisher]
Conclusions: Asymptomatic immigrants are at increased risk for some infections, mainly HBV and tuberculosis. PMID: 31210345 [PubMed - in process]
Should we consider an opt-out system for organ donations?
Condition: Heart Transplantation Intervention: Device: XVIVO heart preservation devices Sponsor: XVIVO Perfusion Not yet recruiting
Condition: Renal Transplant Rejection Intervention: Drug: Fostamatinib Sponsor: Imperial College London Recruiting